Weight: Coren's first inhaler is here! The 20 billion market is heating up rapidly

On January 28th, Colum's declaration of a class 4 imitation of the inhaled isopropyl tobly bromide solution was approved by CDE, the company's first inhaler, which attracted market attention.
meters intranet data show that in China's public medical institutions terminal, the market size of inhalers in 2018 has exceeded 20 billion yuan, 2018-2019 growth rate of more than 10%, the first half of 2020 affected by the epidemic growth rate declined.
Figure 1: Registration of isopropyl bromide solution for inhalation at Hunan Colum Pharmaceuticals Source: CDE Official Website Figure 2: Sales of isopropyl toblybhamide solution for inhalation Source: Isopropyl bromide for anti-ammonium for terminal competition in public medical institutions in China Choline-energy drugs, with strong bronchial smooth muscle relaxation, can significantly improve lung function and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD), relieve the symptoms of respiratory difficulties, improve sleep and quality of life, is one of the main drugs to treat COPD.
research products developed by Grigg Ingham, entered the domestic market in 2004, is the national health insurance catalog Class A varieties.
meters intranet data show that in the first half of 2020 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal inhaler TOP20 products, inhalation of isopropyl tobly bromide solution ranked ninth, the product has grown to more than 1 billion products from 2018.
table 1: Isopropyl tobly bromide inhalants currently under review are involved in the enterprise situation source: MED2.0 China Drug Review Database, the product by the original pharmaceutical companies leading the market, the market share in the first half of 2020 is still more than 90%.
In 2020, the four generics of Shenzhen Mrs. Pharmaceuticals and Four Trump Rite Pharmaceuticals were approved and evaluated as such, and there are currently seven applications for the listing of isopropyl toblyblycide-related inhalants.
By virtue of Colum's strength, after successful approval is expected to become a strong competitor to the original research products, the beginning of 2021 is not more than a month, Colum has seven high-end generic drugs declared on the market and in the review and approval, the next two to three years will also be the big infusion leader new products approved blowout period.
form 2: 2021 to date Colum declared the listing and review of the product situation Source: MED2.0 China Drug Review Database Source: CDE official website, Minet database review data statistics as of January 28, 2021, if there are errors, please refer to the right.